Liang Shengmei, Qiu Xinze, Cai Lulu, Wei Fangyou, Huang Jiean, Liu Shiquan
Department of Gastroenterology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
Transl Cancer Res. 2024 Jul 31;13(7):3704-3717. doi: 10.21037/tcr-23-1883. Epub 2024 Jul 15.
Colon adenocarcinoma (COAD) is among the most prevalent malignancies. Changes to N6-methyladenosine (m6A), the most common RNA modification, can affect how COAD develops. Furthermore, the involvement of long noncoding RNA (lncRNA) in COAD is significant, and it exhibits a close association with m6A modification. Nevertheless, the prognostic significance of lncRNAs that are related to m6A modification in COAD remains unclear. This study aims to establish a m6A-related lncRNA pair signature and reveal its prognostic value in COAD.
The current study utilized data from The Cancer Genome Atlas (TCGA) to investigate the predictive significance of m6A-related lncRNA pair signatures in COAD. The identification of m6A-related lncRNAs was conducted through co-expression analysis using the Pearson correlation coefficient. Then, the lncRNA pairs related to prognosis were identified using univariate Cox regression analysis. Receiver operating characteristic (ROC) curves were produced using the least absolute shrinkage and selection operator (LASSO) penalized with Cox analysis to predict overall survival (OS) in order to build a risk score prognostic model. The relationship among the risk scoring model and clinical characteristics, immune-related variables, and medication sensitivity was examined after identifying independent prognostic factors.
Thirty-five of the 319 lncRNA pairings associated with m6A were linked to a pattern that predicted risk ratings. It was verified that the risk score model was a reliable predictor that stood alone from clinicopathological features. Differences between high- and low-risk groups were found in clinicopathological traits, immune-related variables, and medication sensitivity analysis according to correlation analyses.
Based on paired differentially expressed m6A-related lncRNAs, the proposed COAD prognostic model demonstrated potential clinical predictive value.
结肠腺癌（COAD）是最常见的恶性肿瘤之一。N6-甲基腺苷（m6A）作为最常见的RNA修饰，其变化会影响COAD的发展。此外，长链非编码RNA（lncRNA）在COAD中的作用显著，且与m6A修饰密切相关。然而，COAD中与m6A修饰相关的lncRNAs的预后意义仍不清楚。本研究旨在建立一个与m6A相关的lncRNA对特征，并揭示其在COAD中的预后价值。
本研究利用来自癌症基因组图谱（TCGA）的数据，研究m6A相关lncRNA对特征在COAD中的预测意义。通过使用Pearson相关系数的共表达分析来鉴定与m6A相关的lncRNAs。然后，使用单变量Cox回归分析来鉴定与预后相关的lncRNA对。使用最小绝对收缩和选择算子（LASSO）结合Cox分析生成受试者工作特征（ROC）曲线，以预测总生存期（OS），从而建立风险评分预后模型。在确定独立预后因素后，研究了风险评分模型与临床特征、免疫相关变量和药物敏感性之间的关系。
与m6A相关的319个lncRNA配对中有35个与预测风险评级的模式相关。验证了风险评分模型是一个独立于临床病理特征的可靠预测指标。根据相关性分析，在高风险和低风险组之间发现了临床病理特征、免疫相关变量和药物敏感性分析方面的差异。
基于配对差异表达的与m6A相关的lncRNAs，所提出的COAD预后模型显示出潜在的临床预测价值。
